[go: up one dir, main page]

ES2061040T3 - Procedimiento para la produccion y purificacion de una vacuna para la hepatitis b. - Google Patents

Procedimiento para la produccion y purificacion de una vacuna para la hepatitis b.

Info

Publication number
ES2061040T3
ES2061040T3 ES90907882T ES90907882T ES2061040T3 ES 2061040 T3 ES2061040 T3 ES 2061040T3 ES 90907882 T ES90907882 T ES 90907882T ES 90907882 T ES90907882 T ES 90907882T ES 2061040 T3 ES2061040 T3 ES 2061040T3
Authority
ES
Spain
Prior art keywords
molecular weight
hepatitis
purification
high molecular
contaminant proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90907882T
Other languages
English (en)
Inventor
Zeev Even-Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2061040T3 publication Critical patent/ES2061040T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE PROVEEN PROCESOS PARA PRODUCIR PARTICULAS DE ANTIGENO PURIFICADAS DE LA HEPATITIS B EN LAS CELULAS DE LOS MAMIFEROS. ESTOS METODOS COMPRENDEN EL CULTIVO DE LAS CELULAS QUE PRODUCEN LAS PARTICULAS EN UN MEDIUM DE CULTIVO SUPLEMENTADO CON UN SUERO LIBRE DE PROTEINAS CONTAMINANTES DE ALTO PESO MOLECULAR. DESPUES SE RECUPERA LAS PARTICULAS DE ANTIGENO DE LA HEPATITIS B, YA PURIFICADAS. POSTERIORMENTE, SE RETIRAN LAS MOLECULAS QUE TIENEN UN PESO MOLECULAR SUPERIOR A APROXIMADAMENTE 3 X 10 5 DALTONS, MEDIANTE EL PREFRACCIONAMIENTO; POR EJEMPLO, SI LAS CELULAS A CULTIVAR EN MEDIA QUE CONTIENEN ALTOS NIVELES DE SUERO FETAL, HAN DE RETIRARSE LAS PROTEINAS CONTAMINANTES DE ALTO PESO MOLECULAR QUE PUEDEN INHIBIR EL CRECIMIENTO CELULAR Y ASI SE SIMPLIFICA LA PURIFICACION DEL HBSAG, DADO QUE LAS PROTEINAS CONTAMINANTES DE ALTO PESO MOLECULAR SON LOS PRINCIPALES CONTAMINANTES RETIRADOS EN EL PROCESO DE PURIFICACION.
ES90907882T 1989-02-07 1990-02-07 Procedimiento para la produccion y purificacion de una vacuna para la hepatitis b. Expired - Lifetime ES2061040T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30777789A 1989-02-07 1989-02-07

Publications (1)

Publication Number Publication Date
ES2061040T3 true ES2061040T3 (es) 1994-12-01

Family

ID=23191134

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90907882T Expired - Lifetime ES2061040T3 (es) 1989-02-07 1990-02-07 Procedimiento para la produccion y purificacion de una vacuna para la hepatitis b.

Country Status (13)

Country Link
EP (1) EP0408742B1 (es)
JP (1) JP2825647B2 (es)
KR (1) KR0148119B1 (es)
AT (1) ATE112170T1 (es)
AU (1) AU632575B2 (es)
CA (1) CA2026570C (es)
DE (1) DE69012903T2 (es)
DK (1) DK0408742T3 (es)
ES (1) ES2061040T3 (es)
HK (1) HK183395A (es)
IL (1) IL93304A (es)
RU (1) RU2080876C1 (es)
WO (1) WO1990010058A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
CN103319572B (zh) * 2012-03-20 2015-06-24 北京天坛生物制品股份有限公司 一种乙型肝炎表面抗原的纯化方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442205A (en) * 1981-09-22 1984-04-10 The United States Of America As Represented By The Department Of Health And Human Services Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
US4741901A (en) * 1981-12-03 1988-05-03 Genentech, Inc. Preparation of polypeptides in vertebrate cell culture
JPS6078999A (ja) * 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
FI861417A0 (fi) * 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4742158A (en) * 1986-04-25 1988-05-03 Merck & Co., Inc. Purification of hepatitis pre-S antigens by polymerized serum albumin affinity binding
IL79740A0 (en) * 1986-08-17 1986-11-30 Yeda Res & Dev Hepatitis vaccine
EP0301083A4 (en) * 1987-02-11 1990-09-26 Scripps Clinic And Research Foundation Retroviral expression vectors and methods for producing hbv antigens
JPS63230639A (ja) * 1987-03-19 1988-09-27 Nippon Chem Res Kk 新規なｂ型肝炎ウイルス表面抗原粒子とその製法
US4883865A (en) * 1987-09-30 1989-11-28 Merck & Co. Inc. Recovery of pres2+s antigen
JPH0216975A (ja) * 1988-02-09 1990-01-19 Eugene Tech Internatl Inc 異成分混交性のプレーｓに富んだｂ型肝炎表面抗原

Also Published As

Publication number Publication date
DK0408742T3 (da) 1995-03-20
WO1990010058A2 (en) 1990-09-07
WO1990010058A3 (en) 1990-11-01
IL93304A (en) 1992-09-06
CA2026570A1 (en) 1991-01-08
KR910700071A (ko) 1991-03-13
ATE112170T1 (de) 1994-10-15
DE69012903T2 (de) 1995-05-11
EP0408742B1 (en) 1994-09-28
EP0408742A4 (en) 1992-12-09
JP2825647B2 (ja) 1998-11-18
AU5648590A (en) 1990-09-26
DE69012903D1 (de) 1994-11-03
CA2026570C (en) 2000-05-30
EP0408742A1 (en) 1991-01-23
JPH03503847A (ja) 1991-08-29
HK183395A (en) 1995-12-08
IL93304A0 (en) 1990-11-29
RU2080876C1 (ru) 1997-06-10
KR0148119B1 (ko) 1998-08-17
AU632575B2 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
DE69740002D1 (de) Tierzellen und verfahren für die replikation von influenza viren
DE69330850D1 (de) Verfahren zur Herstellung von Virusimpfstoff aus abgeschwächten Varicella Zoster Viren
ES2150938T3 (es) Produccion mejorada de taxol y taxanos mediante cultivos celulares de especies de taxus.
DE69626022D1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
DK615288A (da) Fermenteringsfremgangsmaade
ATE6402T1 (de) Verfahren zur herstellung von hepatitis b oberflaechenantigen.
DE3786806D1 (de) Reinigung von keuchhustenantigenen.
ES2061040T3 (es) Procedimiento para la produccion y purificacion de una vacuna para la hepatitis b.
ES2084637T3 (es) Procedimiento para la inactivacion biologica de acidos nucleicos.
ES514496A0 (es) "un procedimiento de obtencion de poliosidos capsulares inmunogenos".
JP2633391B2 (ja) 付着的に結合した細胞を有するマトリックスおよびウイルス／ウイルス抗原の製造方法
LU79891A1 (fr) Procede de culture de virus
CO4480040A1 (es) Proceso de purificacion del antigeno de superficie viral hepatitis b que comprende el peptido pres 2
ATE132875T1 (de) Verfahren zur herstellung von zellprotein mit anti-hiv-wirkung
BR8702865A (pt) Processo para aumentar diferenciacao de celula em culturas de tecidos de celulas e meio para crescimento de culturas de tecido de celulas
SE7910054L (sv) Forfarande for framstellning av forsommar-meningo-enzephalitis-virus (fsme-virus)-vacciner
DK214187A (da) Immobilisering af ikke-forankringsafhaengige celler
EP0295605B1 (en) Antibody production-stimulating factor derived from human B lymphoblastoid cell and process for producing antibody by using said stimulating factor
ES2094695A1 (es) Nueva cepa de haloferax gibbonsii, halocina h7 producida por ella y procedimiento de obtencion de ambas.
JPS61162172A (ja) 部分的プロトプラスト作製法

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 408742

Country of ref document: ES